Calleja, Jose Luis
Espin, Jaime
Kaushik, Ankita
Hernandez-Guerra, Manuel
Blissett, Rob
Yehoshua, Alon
Igloi-Nagy, Adam
Funding for this research was provided by:
Gilead Sciences
Article History
Accepted: 22 November 2023
First Online: 15 December 2023
Declarations
:
: Jose Luis Calleja has received consultant and lecturer honoraria from Gilead Sciences, AbbVie, Roche, MSD and Intercept Pharmaceuticals. Ankita Kaushik is an employee and stockholder of Gilead Sciences. Alon Yehoshua is a former employee of Gilead Sciences. Manuel Hernandez-Guerra has received research grants from AbbVie and Gilead Sciences, and has participated in consultant advisories for Bayer, Orphalan and Intercept Pharmaceuticals. Rob Blissett and Adam Igloi-Nagy are paid employees of Maple Health Group, which provides consulting services to Gilead Sciences. Jaime Espin has no competing interests to declare that are relevant to the contents of this article.
: This study was funded by Gilead Sciences.
: All secondary data generated or analyzed during this study are included in the published article or its supplementary materials.
: RB and AIN conceptualized and built the model. JLC, JE, AK, MHG, and AY reviewed and critiqued the model and its results. AIN and RB wrote the manuscript, with review and input from JLC, JE, AK, MHG, and AY. All authors read and approved the final manuscript.
: Not applicable.
: Not applicable.
: Not applicable.
: Model inputs were sourced from data in the public domain. The economic model may be requested from the authors.